KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $258,237.84 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 21,959 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.76, for a total transaction of $258,237.84. Following the completion of the sale, the chief executive officer now owns 216,387 shares of the company’s stock, valued at approximately $2,544,711.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

KalVista Pharmaceuticals Stock Down 3.4 %

Shares of KALV opened at $11.29 on Friday. The company’s fifty day moving average is $11.66 and its 200-day moving average is $11.73. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.21 and a 12 month high of $16.88. The firm has a market cap of $476.30 million, a price-to-earnings ratio of -3.58 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Monday, March 11th. The specialty pharmaceutical company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.09). As a group, research analysts predict that KalVista Pharmaceuticals, Inc. will post -3.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of KalVista Pharmaceuticals by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock worth $16,684,000 after purchasing an additional 151,808 shares during the last quarter. SG Americas Securities LLC grew its stake in KalVista Pharmaceuticals by 5.1% in the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after buying an additional 6,670 shares during the last quarter. AJOVista LLC acquired a new position in KalVista Pharmaceuticals in the 4th quarter valued at $60,000. China Universal Asset Management Co. Ltd. acquired a new position in KalVista Pharmaceuticals in the 4th quarter valued at $49,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in KalVista Pharmaceuticals in the 4th quarter valued at $126,000.

Analyst Ratings Changes

A number of research firms have issued reports on KALV. Needham & Company LLC reiterated a “buy” rating and issued a $35.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday, May 1st. HC Wainwright cut their target price on shares of KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, May 3rd.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.